Trial Profile
A Pilot Study of Tremelimumab - A Monoclonal Antibody Against CTLA-4 in Combination With Trans-Arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), or Cryoablation in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tremelimumab (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Liver cancer
- Focus Adverse reactions
- 31 May 2020 Results (N=58), a pooled analysis of data from two trials ( NCT02821754 and NCT01853618 ) assessing long-term survival and analyze predictors of good response, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 21 Nov 2019 Status changed from active, no longer recruiting to completed.
- 18 Jun 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.